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Abstract 
This article reviews a collection of manuscripts in the field of neurodegenerative disease chosen from what are 
considered by the author to be among the 10 most important and potentially impactful topics or research trends 
of 2020 relevant to the field of experimental and diagnostic neuropathology. A deliberate effort was made to 
provide balance among disease categories covered. The result is a varied selection that includes not just individ-
ual papers but also research topics and trends. The association of COVID-19 with longer-term neurological symp-
toms has launched a research trend fueled by speculation that the SARS-CoV-2 might trigger neurodegenerative 
changes. The onslaught of transcriptomic studies has begun to give way to proteomics, with three transformative 
studies published examining glial contributions to Alzheimer disease, cerebral atherosclerosis in cognitive de-
cline, and the complex sequence of post-translational modifications of the tau protein. Plasma biomarkers for 
Alzheimer disease have continued to make rapid advances, especially around highly sensitive assays capable of 
detecting different forms of abnormal hyperphosphorylated tau in peripheral blood. Two studies using cryo-
electron microscopy showed the power of the approach by continuing to elucidate the diversity of filamentous 
tau inclusions, and a third study gave the first glimpse of α-synuclein aggregates at near atomic resolution. An-
other study continued to delineate how different α-synuclein conformers (“strains”) target specific brain regions 
and lead to neurodegeneration. In Huntington’s disease, we saw compelling molecular data showing how cells 
adapt to endoplasmic reticulum stress through the unfolded protein response. Finally, the role of astrocytes in 
chronic traumatic encephalopathy has emerged as a critical area of interest. 
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Introduction 
In a year like no other, experimental neuropa-
thology research in neurodegeneration persevered. 
Confronted with a devastating pandemic, we en-
dured despite shuttered laboratories, working from 
home, supply shortages, the loss of loved ones and 
a myriad of other challenges. Our laboratories 
demonstrated inspiring resilience, adapting to the 
new landscape and soldiering on. Many rose to the 
challenge, finding purpose and inspiration in adver-
sity. Dr. Rita Levy Montalcini once said, “I should 
Review 
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thank Mussolini for having declared me to be of an 
inferior race. This led me to the joy of working, not 
any more unfortunately in university institutes, but 
in a bedroom.” Upon completing this review of just 
a few of the accomplishments of the past year, it 
was clear that this spirit is alive, the same that com-
pelled Levy-Montalcini to work tirelessly at home to 
study chick embryos using scalpels fashioned from 
sewing needles. The spirit could be felt emanating 
from our colleagues sheltering at home, many also 
literally working in their bedrooms! So, it is with 
great pride and appreciation that we take this look 
back and celebrate the accomplishments of our col-
leagues and recognize just a few of the many trans-
formative advances in 2020. The pandemic is a re-
minder that substantive scientific progress comes 
with great human effort and rarely a “eureka mo-
ment.” Here, we also highlight collaborative efforts, 
research trends, groundbreaking methodologies, 
and tools. A concerted effort was made to seek out 
innovations across all neurodegenerative disease 
categories. Given the readership and mission of this 
journal, we emphasized pathoanatomical studies 
most relevant to neuropathologists and clinical neu-
roscientists. 
1. The long-term neuropathological se-
quelae of COVID-19 
Over the past year, the SARS-CoV-2/COVID-19 
pandemic has permeated essentially every aspect of 
our lives, and research in neurodegenerative disease 
is no exception, launching a new, albeit speculative, 
research trend. Early in the pandemic, neuropa-
thologists began to wonder about the extent to 
which COVID-19 might impact brain health. Theoret-
ically, this could be through direct neurotropism as 
some coronaviruses are known to cause encephali-
tis, or perhaps indirectly through complications re-
lated to critical illness and systemic disease (Mor-
gello, 2020). Early reports documented encephalitis 
in the setting of COVID-19 (Reichard et al., 2020), 
but SARS-CoV-2 encephalitis was considered a rare 
event predominantly restricted to susceptible popu-
lations and of modest public health concern. Larger 
autopsy series emerged, highlighting infarction and 
microthrombi in the brain in the acute setting (Fig-
ure 1), more commonly in hospitalized patients, but 
this too was thought to be uncommon (Bryce et al., 
2020). Nevertheless, researchers began to speculate 
that there may be long-term neurological sequelae 
that follow COVID-19 as examples of post-viral 
tauopathy and neurodegeneration are well docu-
mented and now there is increasing alarm that there 
might be an incipient rise in neurological complica-
tions, including dementia and neurodegeneration, 
that might follow the pandemic (Badrfam & Zan-
difar, 2020). 
Neurologists and other clinicians have been de-
scribing persistent neurological symptomatology in 
COVID-19 survivors, including inattentiveness, 
memory impairment and a constellation of other 
cognitive symptoms (i.e., “brain fog”). These are 
part of an entity now termed the post-acute COVID-
19 syndrome (PACS). The underlying neuropatholog-
ical substrate for these findings remains unclear, but 
the effects of hypoxic-ischemic injury, chronic neu-
roinflammation, toxic encephalopathy from break-
down of the blood brain barrier are candidates. Di-
rect effects of the virus are not completely ruled out, 
and the potential for neurotropic strains to emerge 
remains a possibility. Given the existence of enceph-
alitis lethargica and measles related subacute scle-
rosing panencephalitis, both virus related and asso-
ciated with neurofibrillary tangles, it is not unrea-
sonable to speculate that a degenerative compo-
nent of PACS might exist. Critically, it is imperative 
to understand whether these PACS neurological 
symptoms are progressive and we expect a surge in 
translational studies in the coming years focused on 
the long-term changes that follow COVID-19.  
2. Proteomic analysis: spotlight on mi-
croglial and astrocyte inflammation in 
Alzheimer disease 
In the previous decades, transformative tech-
nologies have enabled large-scale genomic and tran-
scriptomic studies of post-mortem brain tissues that 
have been directed towards neurodegenerative dis-
eases, yielding a flood of data out of which has 
emerged a rich and complex picture of Alzheimer 
disease (AD). But what about the proteins? Owning 
to their relatively more complex chemical struc-
tures, measuring structural changes on the protein 
level in a high throughput manner is much more 
challenging. But now, proteomic technologies have
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Figure 1. Post-mortem findings in a patient with SARS-CoV-2/COVID-19. A. Fresh gross image of a right hemibrain from a 68 male with 
COVID-19 showing diffuse swelling and leptomeningeal hemorrhage. B. Fixed right hemibrain from the same patient showing acute and 
subacute infarction in the distribution of the middle cerebral artery territory. C. Luxol fast blue counterstained hematoxylin and eosin 
(LH&E) section showing subacute hemorrhagic infarction. D. LH&E-stained section from the neocortical white matter in a 29-year-old 
male COVID-19 patient with acute disseminated encephalomyelitis (ADEM). 
 
 
advanced sufficiently, and we are beginning to see 
them take center stage. Here and in the next two 
sections we highlight three such studies. 
The first study, published in Nature Medicine, 
led by Nicholas Seyfried and Allan Levey at Emory 
University, profiled 2,000 brain samples, comparing 
more than 3,000 proteins from multiple cohorts, in-
cluding controls, people with asymptomatic AD neu-
ropathology and those with dementia due to AD 
(Johnson et al., 2020). Cases were derived from a to-
tal of eight collections, including the Religious Or-
ders Study and Memory and Aging Project (ROS-
MAP), Mayo Clinic brain bank, Baltimore Longitudi-
nal Study of Aging (BLSA), Baltimore Coroner’s Of-
fice, Banner Sun Health Research Institute, Mount 
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Sinai School of Medicine Brain Bank, Adult Changes 
in Thought Study (ACT), and University of Pennsylva-
nia School of Medicine Brain Bank. Researchers 
identified 13 different gene sets (“modules”) based 
on co-expression patterns (Figure 2). Of these, six 
were correlated with AD neuropathological features 
(i.e., amyloid plaques, neurofibrillary tangles) or 
cognitive impairment. Of the three that were most 
closely correlated with AD features, two were down-
regulated, including the M1 that was composed of 
proteins involved in synaptic function and the M3 
that tracked with mitochondrial proteins. M4 had 
the strongest correlation with disease traits and 
contained astrocyte and microglial proteins involved 
in sugar metabolism. Intriguingly, many of the pro-
teins in the M4 module were encoded by genes that 
are AD risk loci. Importantly, regardless of their pre-
cise function and role in disease, 27 of them were 
detected in CSF, underscoring their potential utility 
as biomarkers. Because this was funded by the ac-
celerating medicine partnership - AD (AMP-AD) pro-
ject, all of these data are publicly available for the 
research community and will surely catalyze contin-
ued proteomic studies. 
3. Proteomic analysis: the contribution 
of cerebral atherosclerosis to cognitive 
decline 
Another proteomics paper published in Nature 
Neuroscience, also from Emory University led by 
Nicholas Seyfried, Allan Levey, and Thomas S. 
Wingo, examined cerebral atherosclerosis as it re-
lates to cognitive decline and AD (Wingo et al., 
2020). Here, the investigators performed a prote-
ome-wide association study (PWAS), which is similar 
to a genome-wide association study (GWAS), to look 
more broadly at relevant neuropathological 
changes, including amyloid-beta deposition, neuro-
fibrillary tangles, infarcts (both macro and microin-
farcts), cerebral amyloid angiopathy, TAR DNA-bind-
ing protein 43 (TDP-43, transactive response DNA 
binding protein 43 kDa), Lewy body pathology, hip-
pocampal sclerosis, and atherosclerosis. Out of this 
analysis, 114 proteins emerged, independently of 
cerebrovascular risk factors (e.g., hypertension, dia-





Figure 2. Protein network analysis in post-mortem Alzheimer disease (AD) brain. A. Brain tissue from the dorsolateral prefrontal cortex 
from AD patients and compared to cognitively normal subjects with age-related pathology and pathologically negative controls from four 
cohorts. B. A correlation network consisting of 13 modules using 3334 proteins was created and correlated with neuropathological as-
sessments, cell type markers, and the associated biological processes identified using gene ontology (GO) analysis. Images courtesy of Dr. 
Erik C. Johnson, Allan I. Levy, Nicholas T. Seyfried, reproduced with permission under the creative commons license.  
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Figure 3. Co-expression network analysis of protein modules in post-mortem human brain.  A, B. A total of 31 modules were identified 
and protein signatures mapped to cell type. C. These modules were then associated with neuropathological outcomes. D. Differences in 
module eigen proteins were seen modules 3 and 9 for atherosclerosis and Alzheimer disease-related dementia. Images curtesy of Drs. 
Thomas Wingo, Aliza Wingo, Nicholas Seyfried, Allan I. Levey (Emory University School of Medicine). 
 
 
from oligodendrocytes involved in myelination. 
Other genes were involved in mRNA processing and 
splicing. They performed co-expression network 
analysis and 31 modules were identified, with five 
being linked independently to cerebral atheroscle-
rosis. This analysis pointed to oligodendrocyte func-
tion alongside downregulation of mRNA processing 
in neurons and astrocytes with impaired synaptic 
functioning in brains of individuals with cerebral ath-
erosclerosis. This may be related to another finding 
of higher levels of neurofilament light (NfL) and me-
dium (NfM) which were higher in cases with athero-
sclerosis, perhaps reflecting axonal injury. This study 
will drive continued research into the effects of cer-
ebral atherosclerosis on the brain proteome and 
their contribution to AD. 
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4. Proteomic analysis: A high-resolu-
tion quantitative map of post-transla-
tional modifications of tau pro-
teoforms 
Neurofibrillary tangles exist in a spectrum of 
morphological forms that are immediately recog-
nizable using immunohistochemistry with antisera 
targeting hyperphosphorylated tau (p-tau). The ear-
liest detectable neurofibrillary change is the pres-
ence faint granular p-tau labeling in pre-tangles; this 
staining accumulates and coalesces into intracellular 
tangles that eventually become extracellular 
(“tombstone” or “ghost”) tangles following neuronal 
death. Understanding the molecular events that cor-
respond to this sequence would be extremely help-
ful for developing the next generation of diagnostics 
(see below) and therapeutics. The pathobiology of 
tau pathology is complex, with multiple tau isoforms 
undergoing innumerable secondary structural mod-
ifications in disease states beyond just hyperphos-
phorylation, including truncation, acetylation, ubiq-
uitination, glycosylation and methylation. It has 
been challenging to temporally map the order of 
these events using traditional approaches (e.g., 
phospho-specific tau antisera-based methods) 
which lack the ability to synchronously and compre-
hensively detect these critical changes. 
In the last proteomics paper, published in Cell 
in November of 2020, a powerful study, led by Dr. 
Judith Steene at Boston Children’s Hospital, detailed 
their focused analysis that was entirely directed to-
wards the tau protein (Wesseling et al., 2020). They 
deployed a previously published mass spectrome-
try-based assay, that they term “FLEXI-tau” (Mair et 
al., 2016), which allowed them to generate a high-
resolution quantitative proteomic map of 95 post-
translational modifications on multiple tau isoforms 
from 91 human post-mortem brains. They then used 
unsupervised analyses to predict sequential addi-
tion of modifications. They found that while there is 
a great degree of heterogeneity, there appears to be 
a minimal set of modifications that develop in a pro-
cessive fashion and are associated with tissue frac-
tions associated with disease stage as well as tau 
seeding activity. The analysis also highlighted a spe-
cific alternatively spliced tau isoform with four mi-
crotubule binding domain repeats (4R), but lacking 
N-terminal domain inserts (0N). The 0N4R isoform is 
highly overrepresented in aggregates isolated from 
early disease stages alongside modifications associ-
ated with increased negative charge in the proline-
rich region and decreased positive charge in the mi-
crotubule binding domain. These findings are prom-
ising because they give us the most comprehensive 
picture of tau secondary structure and provide a 
pathway towards continuing to advance the bi-
omarkers that are rapidly evolving and identify the 
critical modifications that are responsible for the 
pathogenicity of tau paving the way towards new 
therapeutics. 
5. Plasma biomarkers for Alzheimer 
disease 
Obtaining a definitive diagnosis of a neuro-
degenerative disease continues to require an au-
topsy, the perennial gold standard, but continued 
advances in blood-based biomarkers are continuing 
to challenge this and offer a low-cost, convenient al-
ternative. Over the past decade, substantial pro-
gress has been made in our ability to assess molecu-
lar changes in the central nervous system using non-
invasive amyloid positron emission tomography 
(PET) scans and cerebrospinal fluid (CSF) markers. 
Yet these modalities are expensive, inconvenient 
and come with a mild degree of risk. The long-sought 
development of a blood-based biomarker for Alz-
heimer disease (AD), had been considered unrealis-
tic because the levels of brain proteins in the blood 
had been thought to be simply too low to be reliably 
and reproducibly detected. Further, there was con-
cern that the extent to which blood levels of various 
factors reflect ongoing disease processes might be 
too disconnected or tangential to be clinically useful. 
So, it comes as no surprise that the research com-
munity has been stunned by the rapid progress in 
blood-based biomarkers in neurodegeneration. This 
year a milestone was achieved, with the “Preciv-
ityAD™” mass-spec amyloid-β assay, which was de-
veloped at Washington University Saint Louis in the 
laboratory directed by Dr. Randall Bateman, receiv-
ing approval under the Clinical Laboratory Improve-
ment Amendments (CLIA) as well as an FDA break-
through designation. However, this is only half of 
the story. The other essential neuropathological 
hallmark of AD, the neurofibrillary tangle composed 
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of abnormal tau, is also required for a diagnosis. Re-
markably, similar rapid progress is being made on 
this front with a series of groundbreaking studies 
that were published over that past year, continuing 
the momentum. 
In previous years, the first papers emerged de-
scribing highly sensitive immunoassays identifying 
p-tau phosphorylated at threonines 181 or 217 as 
early promising biomarkers. In 2020, phospho-thre-
onine 231 (p-tau231) was reported to be an excel-
lent early marker for tau pathology in CSF (Suárez-
Calvet et al., 2020). This was followed up with results 
from a study using an ultrasensitive Single molecule 
array (SIMOA) for the quantification of p-tau231 in 
blood plasma (Ashton et al., 2021). The study in-
cluded a total of 588 subjects and successfully differ-
entiated AD from amyloid-β negative cognitively 
normal individuals. Plasma p-tau231 also differenti-
ated AD patients from non-AD neurodegenerative 
disorders and amyloid-β negative MCI patients. In 
samples taken from patients with post-mortem au-
topsy confirmation, plasma p-tau231 was extremely 
accurate in identifying AD neuropathology in com-
parison to non-AD neurodegenerative disorders 
(AUC = 0.99). Plasma p-tau231 was highly correlated 
with other AD biomarkers, i.e., CSF p-tau231, tau 
PET ([18F]MK-6240) and amyloid-β PET ([18F]AZD). 
The elevations in p-tau231 were a very early change, 
preceding amyloid-β PET and plasma p-tau181. 
Plasma p-tau231 had the power to resolve even sub-
tle differences, differentiating subjects across even 
early Braak stages. Together, we are witnessing im-
pressive progress in blood-based AD biomarkers 
with the potential to detect the earliest disease 
stages, prior to significant irreversible brain destruc-
tion, and enable the next generation of clinical trials. 
 
6. Cryo-electron microscopy: ultrahigh 
resolution structure of tau in cortico-
basal degeneration 
In 2017, the Nobel Prize in Chemistry was 
awarded to Jacques Dubochet, Joachim Frank and 
Richard Henderson for cryo-electron microscopy 
(cryo-EM). The approach, which involves cooling 
samples to cryogenic temperatures and embedding 
them in an environment of vitreous water, has been 
in development since the 1970s, but recent tech-
nical advances in detectors and software algorithms 
have enabled solving molecular structures at near-
atomic resolution. The power of cryo-EM was first 
demonstrated that year to the neurodegenerative 
disease research community when the approach 
was applied to paired-helical filament tau fibrils in 
Alzheimer disease, illuminating at near atomic reso-
lution the C-shaped conformation of the core (Fitz-
patrick et al., 2017). This report was quickly followed 
by the solving of the structure for the J-shaped tau 
filament core in Pick disease which contains addi-
tional residues making it slightly longer than in AD 
(Falcon et al., 2018). Next came chronic traumatic 
encephalopathy, which has a similar C-shape to that 
in Alzheimer disease (Falcon et al., 2019). Also de-
scribed was an additional non-proteinaceous hydro-
phobic density that has yet to be defined. These 
findings support the notion that there exists a spec-
trum of hitherto unrecognized tau structural fea-
tures and conformations, often termed “strains” in 
a nod to the prion literature that has informed much 
of the research on protein misfolding, that may be 
distinct in different disease states. Now, we are con-
tinuing to see additional insights with two papers 
describing the structure of the tau filament core in 
corticobasal degeneration as well as another which 
is the first cryo-EM structure of α-synuclein (see next 
section). 
In a paper published in Cell in February 2020, a 
team led by Anthony Fitzpatrick at Columbia Univer-
sity detailed their study showing the cryo-EM struc-
ture of filaments from corticobasal degeneration 
(Arakhamia et al., 2020). In additional analyses, they 
further integrated these cryo-EM structures and 
those from AD with mass spectrometry data to lo-
calize post-translational secondary modifications. A 
separate study, published in Nature, led by Sjors 
Scheres and Michel Goedert at the MRC Laboratory 
of Molecular Biology in Cambridge, England, U.K. 
(Zhang et al., 2020). This team also showed a similar 
structure in CBD (Figure 4). Together, in addition to 
providing a validated atomic level resolution C-
shaped structure of the tau filament in CBD, these 
studies both revealed a density buried in the struc-
ture that represents a molecule of unknown iden-
tity, akin to what was identified in CTE. The fibrils in 
CBD are composed entirely of tau with 4 microtu-
bule binding domain repeats (4R), which differs from 
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Figure 4. Cryo-EM of tau filaments in corticobasal degeneration. A. Negative-stain electron micrographs of type I and type II tau filaments 
extracted from the frontal cortex of CBD. B. Cryo-EM maps of type I and type II tau filaments from the frontal cortex of CBD. C. Top, the 
microtubule-binding repeats (R1–R4) of tau and the sequence after R4 that is present in the core of CBD filaments (all shown in different 
colors). Bottom, atomic model of the CBD type II tau filament. The extra density is shown in light blue, with K290, K294 and K370 indicated. 
Images courtesy of Drs. Wenjuan Zhang, Sjors Scheres and Michel Goedert MRC Laboratory of Molecular Biology, Cambridge). 
 
 
Pick disease which is composed of 3R tau as well as 
AD and CTE which are mixed 3R and 4R. Additional 
future studies directed towards further delineation 
of the diversity of tau filament structures has the po-
tential to pave the way towards improved diagnos-
tics and advancing our understanding of the diver-
sity of conformers in tauopathy that may be associ-
ated with different clinical symptomatology. 
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7. Cryo-electron microscopy: ultrahigh 
resolution structures of α-synuclein 
conformers 
This year we also saw reports of the first ultra-
high resolution cryo-EM structures of α-synuclein fi-
brils published in Nature also from Sjors Scheres and 
Michel Goedert at the MRC Laboratory of Molecular 
Biology (Schweighauser et al., 2020). The synucle-
inopathies are a group of neurodegenerative disor-
ders that include Parkinson’s disease (PD), PD de-
mentia, diffuse Lewy body disease (DLBD) and mul-
tiple system atrophy (MSA). Co-first authors 
Schweighauser and Shi et al., studied three cases of 
DLBD and five with MSA. In MSA, they found two 
types of filament, that they termed type 1 and type 
2, each with filaments with different protofibrils that 
make up the core. The conformation of α-synuclein 
filaments derived from DLBD brains by cryo-EM pre-
cluded 3D imaging, so 2D class averaging was used 
to show that there were differences in the structure 
from MSA. Overall, these structural differences are 
of great interest as accumulating evidence suggests 
that α-synuclein might behave in a prion-like man-
ner, with templating and propagation of abnormal 
structures/conformers. This knowledge may be 
helpful in understanding the pathogenesis and nat-
ural history of the synucleinopathies, and especially 
in the development of specific α-synuclein PET trac-
ers, which have been so far elusive. 
8. Characterizing α-synuclein strains 
The α-synucleinopathies, including Parkinson 
disease, diffuse Lewy body disease, and dementia 
with Lewy bodies, while linked by aggregation of α-
synuclein, have been hypothesized to diverge based 
on the prion-like properties unique disease confor-
mational structural folding that templates replica-
tion of the abnormality. These strains are hypothe-
sized to have different properties and may influence 
neuropathological features and symptomatology.  
This year, a study was published that took us 
one step closer to understanding the pathobiology 
and diversity of α-synuclein strains. In an elegant set 
of experiments, Lau et al. recreated an array of α-
synuclein fibrils with different confirmations in vitro 
using recombinant proteins by altering buffer condi-
tions (Lau et al., 2020). They generated a host of fi-
brils that varied in their biophysical properties and 
compared them with those derived from human 
post-mortem brain samples. Then, the fibrils were 
inoculated into a transgenic mouse line that overex-
presses human mutant α-synuclein and observed 
them. Over time, the mice developed a range of 
traits that were strain specific, including aggregate 
morphology, incubation periods and behavioral 
changes, that could be propagated serially (Figure 
5). In the brains of these animals, distinct neuroana-
tomical vulnerability was observed that was dictated 
by strain type. These findings give us an additional 
model for testing questions related to how these dif-
ferent α-synuclein conformers target specific cells 
and brain regions leading to neurodegeneration. 
 
 
Figure 5. Distinct midbrain pathology in transgenic α-synuclein 
(M83) mice inoculated with salt (S) fibrils or no salt (NS) fibrils. 
A. The NS fibril-injected mice show the “Lewy body-like” α-synu-
clein pathology. B. The S fibril-injected mice exhibit the “ring-
like” α-synuclein pathology. Both images show stains with the 
EP1536Y antibody that recognizes synuclein phosphorylated at 
serine 129. Images courtesy of Dr. Joel Watts (University of To-
ronto). 
 
9. Huntington’s disease and chorea 
Abnormalities in proteostasis are a key feature 
of essentially all neurodegenerative disorders. This 
change is associated with endoplasmic reticulum 
(ER) stress, which then triggers the unfolded protein 
response (UPR). XBP1 is a key mediator of the ER 
stress response thought to be a master regulator of 
the UPR that drives the adaptation response to re-
cover proteostasis through a number of mecha-
nisms. 
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In a series of compelling experiments, a team 
from the University of Chile showed that treatment 
with IGF2, a factor that they previously implicated as 
a downstream effector of XBP1 in animal models de-
ficient in XBP1, may be an important contributor to 
this finding (García-Huerta et al., 2020). Treatment 
with IGF1 led to a marked reduction in the burden of 
intracellular aggregates of mutant huntingtin in cel-
lular models, including an induced pluripotent stem 
cell (iPSC)-derived model of medium spiny neurons 
from HD patients. When the autophagy and the 
ubiquitin proteasome were assessed, they surpris-
ingly found that these pathways were not responsi-
ble. Remarkably, they found IGF2 signaling en-
hanced secretion of soluble mutant huntingtin into 
exosomes/microvesicles. These findings were not 
limited to cell culture but were recapitulated when 
IGF2 was infused into the brain of HD mice. Finally, 
these findings were validated in human tissue sam-
ples, with a reduction in IGF2 in post-mortem HD 
brain and blood. These findings take us one step 
closer to understanding the role of the UPR in HD 





Figure 6. Immunofluorescence microscopy in a sulcal region from an individual who passed away in their 20s with chronic traumatic 
encephalopathy (CTE). A. Low power image highlighting two perivascular lesions. B. High power image showing staining with markers for 
astroglia (GFAP, blue), neurons (MAP2, green) and abnormal hyperphosphorylated p-tau (AT8; green). White arrows mark colocalization. 
In these lesions, there is only MAP2 overlap with p-tau. No GFAP/AT8 colocalization was seen in this case. Scale bar is 50 um. Images 
courtesy of Dr. Jonathan Cherry and Ann McKee (Boston University and Boston VA). 
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10. Chronic traumatic encephalopathy: 
what about the astrocytes? 
Slightly over ten years ago, chronic traumatic 
encephalopathy (CTE) was propelled to the fore of 
neurodegenerative disease research where it has re-
mained. Since that time, broad consensus has 
emerged among neuropathologists that CTE has a 
distinct neuropathological presentation that is dis-
tinguishable from other tauopathies, with a unique 
pathognomonic perivascular lesion that was codi-
fied in consensus criteria (McKee et al., 2016). In this 
report, the pathognomonic lesion was described as 
consisting of “p-tau aggregates in neurons, astro-
cytes, and cell processes around small vessels in an 
irregular pattern at the depths of the cortical sulci”. 
While this working definition was considered suffi-
ciently precise, confusion emerged and persisted in 
the literature around the perivascular astrocytes in 
aging related tau astrogliopathy (ARTAG) (Kovacs et 
al., 2016) that can generally be differentiated based 
on the absence of neurons and localization in the 
white matter or subpial compartments. Clarification 
was not sufficient to put the astrocyte question to 
rest (McKee et al., 2020). 
Setting aside ARTAG, there is a tremendous 
burden of p-tau positive gray matter astrocytes in 
CTE. A study led by John Trojanowski at the Univer-
sity of Pennsylvania and William Stewart at the Uni-
versity of Glasgow published in Brain Communica-
tions sought to neuroanatomically map these astro-
cytes and found a preferential accumulation in the 
sulcal depths, the precise region that is biomechani-
cally vulnerable in CTE and where tau pathology first 
emerges (Arena et al., 2020). This is in contrast to 
neuronal tau pathology which they found was more 
diffuse. This seems to suggest that astrocyte pathol-
ogy is an early event. In another study published in 
Brain Pathology led by Ann McKee and John Crary 
(writer of this review), a spectrum of cases that also 
included very early CTE lesions was able to pinpoint 
abnormal tau in early pathognomonic lesions to 
perivascular neurons (Figure 6), but not astrocytes, 
which appeared to accumulate later in the disease 
progression (Cherry et al., 2020). This tau pathology 
consisted predominantly of tau isoforms containing 
four microtubule binding domain repeats (4R tau), 
an isoform that has been proposed to be especially 
toxic given its increased propensity towards aggre-
gation. Together, these findings point to a complex 
picture of evolving tau pathology in neurons and as-
trocytes early in CTE and we expect that research in 
the coming years around the role of astrocytes in 
early CTE will intensify. 
Acknowledgement 
Dr. Crary receives research funding from the 
NIH (P30AG066514, R01AG054008, R01NS095252, 
R01AG062348, R01NS086736, U54NS115266, 
U54NS115322). We further acknowledge the Rain-
water Charitable Trust/Tau Consortium, David and 
Elsie Werber, Alexander Saint Amand Scholar Award 
and Karen Strauss Cook Research Scholar Award. 
References
Arakhamia, T., Lee, C. E., Carlomagno, Y., Duong, D. M., Kundinger, S. R., 
Wang, K., Williams, D., DeTure, M., Dickson, D. W., Cook, C. N., Seyfried, 
N. T., Petrucelli, L., & Fitzpatrick, A. W. P. (2020). Posttranslational 
Modifications Mediate the Structural Diversity of Tauopathy Strains. 
Cell, 180(4), 633-644.e12. https://doi.org/10.1016/j.cell.2020.01.027  
Arena, J. D., Johnson, V. E., Lee, E. B., Gibbons, G. S., Smith, D. H., 
Trojanowski, J. Q., & Stewart, W. (2020). Astroglial tau pathology alone 
preferentially concentrates at sulcal depths in chronic traumatic 
encephalopathy neuropathologic change. Brain Communications, 2(2), 
fcaa210. https://doi.org/10.1093/braincomms/fcaa210  
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-
Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, 
A., Gauthier, S., Vanmechelen, E., Zetterberg, H., Rosa-Neto, P., & 
Blennow, K. (2021). Plasma p-tau231: A new biomarker for incipient 
Alzheimer’s disease pathology. Acta Neuropathologica.  
https://doi.org/10.1007/s00401-021-02275-6  
Badrfam, R., & Zandifar, A. (2020). From encephalitis lethargica to 
COVID-19: Is there another epidemic ahead? Clinical Neurology and 
Neurosurgery, 196, 106065.   
https://doi.org/10.1016/j.clineuro.2020.106065  
Bryce, C., Grimes, Z., Pujadas, E., Ahuja, S., Beasley, M. B., Albrecht, R., 
Hernandez, T., Stock, A., Zhao, Z., Rasheed, M. A., Chen, J., Li, L., Wang, 
D., Corben, A., Haines, K., Westra, W., Umphlett, M., Gordon, R. E., 
Reidy, J., … Fowkes, M. (2020). Pathophysiology of SARS-CoV-2: 
Targeting of endothelial cells renders a complex disease with 
thrombotic microangiopathy and aberrant immune response. The 
Mount Sinai COVID-19 autopsy experience. MedRxiv, 
2020.05.18.20099960. https://doi.org/10.1101/2020.05.18.20099960  
Cherry, J. D., Kim, S. H., Stein, T. D., Pothast, M. J., Nicks, R., Meng, G., 
Huber, B. R., Mez, J., Alosco, M. L., Tripodis, Y., Farrell, K., Alvarez, V. E., 
McKee, A. C., & Crary, J. F. (2020). Evolution of neuronal and glial tau 
isoforms in chronic traumatic encephalopathy. Brain Pathology (Zurich, 
Switzerland). https://doi.org/10.1111/bpa.12867  
Free Neuropathology 2:9 (2021) John F. Crary 




Falcon, B., Zhang, W., Murzin, A. G., Murshudov, G., Garringer, H. J., 
Vidal, R., Crowther, R. A., Ghetti, B., Scheres, S. H. W., & Goedert, M. 
(2018). Structures of filaments from Pick’s disease reveal a novel tau 
protein fold. Nature, 561(7721), 137–140.   
https://doi.org/10.1038/s41586-018-0454-y  
Falcon, B., Zivanov, J., Zhang, W., Murzin, A. G., Garringer, H. J., Vidal, 
R., Crowther, R. A., Newell, K. L., Ghetti, B., Goedert, M., & Scheres, S. 
H. W. (2019). Novel tau filament fold in chronic traumatic 
encephalopathy encloses hydrophobic molecules. Nature, 568(7752), 
420–423. https://doi.org/10.1038/s41586-019-1026-5  
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., 
Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. 
W. (2017). Cryo-EM structures of tau filaments from Alzheimer’s 
disease. Nature, 547(7662), 185–190.   
https://doi.org/10.1038/nature23002  
García-Huerta, P., Troncoso-Escudero, P., Wu, D., Thiruvalluvan, A., 
Cisternas-Olmedo, M., Henríquez, D. R., Plate, L., Chana-Cuevas, P., 
Saquel, C., Thielen, P., Longo, K. A., Geddes, B. J., Lederkremer, G. Z., 
Sharma, N., Shenkman, M., Naphade, S., Sardi, S. P., Spichiger, C., 
Richter, H. G., … Hetz, C. (2020). Insulin-like growth factor 2 (IGF2) 
protects against Huntington’s disease through the extracellular disposal 
of protein aggregates. Acta Neuropathologica, 140(5), 737–764. 
https://doi.org/10.1007/s00401-020-02183-1  
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., 
Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., 
Thambisetty, M., Montine, T. J., Lee, E. B., Trojanowski, J. Q., Beach, T. 
G., Reiman, E. M., Haroutunian, V., Wang, M., Schadt, E., … Seyfried, N. 
T. (2020). Large-scale proteomic analysis of Alzheimer’s disease brain 
and cerebrospinal fluid reveals early changes in energy metabolism 
associated with microglia and astrocyte activation. Nature Medicine, 
26(5), 769–780. https://doi.org/10.1038/s41591-020-0815-6  
Kovacs, G. G., Ferrer, I., Grinberg, L. T., Alafuzoff, I., Attems, J., Budka, 
H., Cairns, N. J., Crary, J. F., Duyckaerts, C., Ghetti, B., Halliday, G. M., 
Ironside, J. W., Love, S., Mackenzie, I. R., Munoz, D. G., Murray, M. E., 
Nelson, P. T., Takahashi, H., Trojanowski, J. Q., … Dickson, D. W. (2016). 
Aging-related tau astrogliopathy (ARTAG): Harmonized evaluation 
strategy. Acta Neuropathologica, 131(1), 87–102.   
https://doi.org/10.1007/s00401-015-1509-x  
Lau, A., So, R. W. L., Lau, H. H. C., Sang, J. C., Ruiz-Riquelme, A., Fleck, S. 
C., Stuart, E., Menon, S., Visanji, N. P., Meisl, G., Faidi, R., Marano, M. 
M., Schmitt-Ulms, C., Wang, Z., Fraser, P. E., Tandon, A., Hyman, B. T., 
Wille, H., Ingelsson, M., … Watts, J. C. (2020). α-Synuclein strains target 
distinct brain regions and cell types. Nature Neuroscience, 23(1), 21–31. 
https://doi.org/10.1038/s41593-019-0541-x  
Mair, W., Muntel, J., Tepper, K., Tang, S., Biernat, J., Seeley, W. W., Kosik, 
K. S., Mandelkow, E., Steen, H., & Steen, J. A. (2016). FLEXITau: 
Quantifying Post-translational Modifications of Tau Protein in Vitro and 
in Human Disease. Analytical Chemistry, 88(7), 3704–3714. 
https://doi.org/10.1021/acs.analchem.5b04509  
McKee, A. C., Cairns, N. J., Dickson, D. W., Folkerth, R. D., Keene, C. D., 
Litvan, I., Perl, D. P., Stein, T. D., Vonsattel, J.-P., Stewart, W., Tripodis, 
Y., Crary, J. F., Bieniek, K. F., Dams-O’Connor, K., Alvarez, V. E., Gordon, 
W. A., & TBI/CTE group. (2016). The first NINDS/NIBIB consensus 
meeting to define neuropathological criteria for the diagnosis of chronic 
traumatic encephalopathy. Acta Neuropathologica, 131(1), 75–86. 
https://doi.org/10.1007/s00401-015-1515-z  
McKee, A. C., Stein, T. D., Crary, J. F., Bieniek, K. F., Cantu, R. C., & Kovacs, 
G. G. (2020). Practical Considerations in the Diagnosis of Mild Chronic 
Traumatic Encephalopathy and Distinction From Age-Related Tau 
Astrogliopathy. Journal of Neuropathology and Experimental Neurology, 
79(8), 921–924. https://doi.org/10.1093/jnen/nlaa047  
Morgello, S. (2020, August). Coronaviruses and the central nervous 
system. Journal of Neurovirology; J Neurovirol.   
https://doi.org/10.1007/s13365-020-00868-7  
Reichard, R. R., Kashani, K. B., Boire, N. A., Constantopoulos, E., Guo, Y., 
& Lucchinetti, C. F. (2020). Neuropathology of COVID-19: A spectrum of 
vascular and acute disseminated encephalomyelitis (ADEM)-like 
pathology. Acta Neuropathologica, 140(1), 1–6.   
https://doi.org/10.1007/s00401-020-02166-2  
Schweighauser, M., Shi, Y., Tarutani, A., Kametani, F., Murzin, A. G., 
Ghetti, B., Matsubara, T., Tomita, T., Ando, T., Hasegawa, K., Murayama, 
S., Yoshida, M., Hasegawa, M., Scheres, S. H. W., & Goedert, M. (2020). 
Structures of α-synuclein filaments from multiple system atrophy. 
Nature, 585(7825), 464–469.  
https://doi.org/10.1038/s41586-020-2317-6  
Suárez-Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., 
Milà-Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., 
Shekari, M., Grau-Rivera, O., Arenaza-Urquijo, E. M., Sala-Vila, A., 
Sánchez-Benavides, G., González-de-Echávarri, J. M., Kollmorgen, G., 
Stoops, E., Vanmechelen, E., Zetterberg, H., … ALFA Study. (2020). Novel 
tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial 
stages of the preclinical Alzheimer’s continuum when only subtle 
changes in Aβ pathology are detected. EMBO Molecular Medicine, 
12(12), e12921. https://doi.org/10.15252/emmm.202012921  
Wesseling, H., Mair, W., Kumar, M., Schlaffner, C. N., Tang, S., 
Beerepoot, P., Fatou, B., Guise, A. J., Cheng, L., Takeda, S., Muntel, J., 
Rotunno, M. S., Dujardin, S., Davies, P., Kosik, K. S., Miller, B. L., Berretta, 
S., Hedreen, J. C., Grinberg, L. T., … Steen, J. A. (2020). Tau PTM Profiles 
Identify Patient Heterogeneity and Stages of Alzheimer’s Disease. Cell, 
183(6), 1699-1713.e13. https://doi.org/10.1016/j.cell.2020.10.029  
Wingo, A. P., Fan, W., Duong, D. M., Gerasimov, E. S., Dammer, E. B., Liu, 
Y., Harerimana, N. V., White, B., Thambisetty, M., Troncoso, J. C., Kim, 
N., Schneider, J. A., Hajjar, I. M., Lah, J. J., Bennett, D. A., Seyfried, N. T., 
Levey, A. I., & Wingo, T. S. (2020). Shared proteomic effects of cerebral 
atherosclerosis and Alzheimer’s disease on the human brain. Nature 
Neuroscience, 23(6), 696–700.  
https://doi.org/10.1038/s41593-020-0635-5  
Zhang, W., Tarutani, A., Newell, K. L., Murzin, A. G., Matsubara, T., 
Falcon, B., Vidal, R., Garringer, H. J., Shi, Y., Ikeuchi, T., Murayama, S., 
Ghetti, B., Hasegawa, M., Goedert, M., & Scheres, S. H. W. (2020). Novel 
tau filament fold in corticobasal degeneration. Nature, 580(7802), 283–
287. https://doi.org/10.1038/s41586-020-2043-0  
 
 
 
  
 
